senolytic peptide foxo4-dri human study Frontiers FOXO4-DRI 10mg Development of a novel senolytic

Two-year effects of GLP1 in adults with overweight or obesity: The STEP 5 trial

The authors reported that the combination was generally tolerated across the tested levels, with adverse events predominantly gastrointestinal and graded mild to moderate, and that the pharmacokinetic profile was consistent with once-weekly administration in the trial design

10.1016/S0735-1097(00)01093-7 J Am Coll Cardiol

This powerful peptide triggers genuine regenerative processes in your skin, but regeneration isn't always pretty at first

10.1016/0968-000490148-x Trends Biochem Sci

The stability of the Lypo-Spheric Glutathione deteriorates rapidly once an individual packet is opened